Neonatal admission to NICU · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in neonatal admission to NICU compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Need of misoprostol for cervical ripening · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score probably leads to lower need of misoprostol for cervical ripening compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Meconium staining of amniotic fluid · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in meconium staining of amniotic fluid compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Apgar score less than 7 at 5 minutes · women with singleton cephalic fetuses undergoing assessment for pre‐induction cervical ripening.
Bishop score showed no clear difference in apgar score at 5 minutes less than 7 compared with transvaginal ultrasound (moderate certainty).
1 finding from 1 review
Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Intervention not reported
Perinatal death · women with an abnormal cardiotocograph (CTG) in labour
1 finding from 1 review
Intervention not reported
Caesarean section (all indications) Â · women with an abnormal CTG in labour
It is very uncertain whether the intervention changes caesarean section (all indications) Â (very low certainty).
1 finding from 1 review
Intervention not reported
Neonatal encephalopathy  · women with an abnormal CTG in labour
1 finding from 1 review